KRW 4160.0
(-1.42%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 737.2 Million KRW | -94.64% |
2022 | 13.74 Billion KRW | -73.92% |
2021 | 52.7 Billion KRW | 113.65% |
2020 | 24.66 Billion KRW | 35.99% |
2019 | 18.14 Billion KRW | 68.47% |
2018 | 10.76 Billion KRW | 599.23% |
2017 | 1.53 Billion KRW | 2.15% |
2016 | 1.5 Billion KRW | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 10.1 Billion KRW | 879.31% |
2024 Q1 | 1.04 Billion KRW | 42.39% |
2023 Q1 | 13.47 Billion KRW | -1.98% |
2023 Q4 | 737.2 Million KRW | -80.65% |
2023 Q3 | 3.81 Billion KRW | 6.86% |
2023 Q2 | 3.56 Billion KRW | -73.53% |
2023 FY | 737.2 Million KRW | -94.64% |
2022 Q4 | 13.74 Billion KRW | -7.9% |
2022 Q2 | 14.79 Billion KRW | -77.2% |
2022 Q1 | 64.91 Billion KRW | 23.17% |
2022 Q3 | 14.92 Billion KRW | 0.85% |
2021 Q4 | 52.7 Billion KRW | -1.13% |
2021 Q3 | 53.31 Billion KRW | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 23.72 Billion KRW | 96.893% |
CMG Pharmaceutical Co., Ltd. | 19.74 Billion KRW | 96.266% |
Celltrion Pharm, Inc. | 162.52 Billion KRW | 99.546% |
Huons Global Co., Ltd. | 254.93 Billion KRW | 99.711% |
DongKook Pharmaceutical Co., Ltd. | 104.74 Billion KRW | 99.296% |
Enzychem Lifesciences Corporation | 5.65 Billion KRW | 86.968% |
Humedix Co., Ltd. | 2.7 Billion KRW | 72.714% |
Boditech Med Inc. | 10.56 Billion KRW | 93.024% |
EuBiologics Co., Ltd. | 14.77 Billion KRW | 95.012% |
FutureChem Co.,Ltd | 3.68 Billion KRW | 79.981% |
Huons Co., Ltd. | 124.61 Billion KRW | 99.408% |
AptaBio Therapeutics Inc. | 13.93 Billion KRW | 94.709% |